NCT02289300 - A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients | Biotech Hunter

Timeline

Start Date

January 31, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

December 31, 2021

Conditions

Liver FibrosisHEPATITIS B CHRONICHepatocellular Carcinoma

Interventions

DRUG

DCB-BO1202

"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"

DRUG

Placebo

"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"

DRUG

DCB-BO1202+Placebo

"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"

Trial Locations (1)

100

National Taiwan University Hospital, Taipei